Abstract:
The aim of this study was to evaluate the efficacy of fludarabine treatment in patients suffering from refractory rheumatoid arthritis. Four patients affected by refractory seropositive rheumatoid arthritis underwent treatment with fludarabine for 6 months. The drug was administered intravenously at a dose of 25 mg the first month in a single infusion, and then monthly for 5 months at a dose of 25 mg for 3 consecutive days. All four patients obtained no clinical benefit from the treatment; moreover, inflammation indices worsened and the prednisone dosage was increased during the trial, in spite of a significant fall in CD4+ T cells. In our experience low-dose fludarabine is not useful in the treatment of refractory rheumatoid arthritis.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 1 September 1999 / Accepted: 2 March 2000
Rights and permissions
About this article
Cite this article
Biasi, D., Caramaschi, P., Carletto, A. et al. Unsuccessful Treatment with Fludarabine in Four Cases of Refractory Rheumatoid Arthritis. Clin Rheumatol 19, 442–444 (2000). https://doi.org/10.1007/s100670070002
Published:
Issue Date:
DOI: https://doi.org/10.1007/s100670070002